Isopropanolic Cimicifuga racemosa is favorable on bone markers but neutral on an osteoblastic cell line.
Postmenopausal women treated with an isopropanolic extract of Cimicifuga racemosa underwent a decrease in the urinary concentration of N-telopeptides, a marker of bone resorption, and an increase in alkaline phosphatase, a marker of bone formation, at the third month of therapy. Serum from treated women did not modify the activity of alkaline phosphatase or the expression of three genes, runt-related transcription factor-2 (Runx-2), alkaline phosphatase, and osteocalcin, when added to the MC3T3-E1 osteoblastic cell line.
Research Foundation, Hospital Clínico Universitario, Valencia, Spain.
Miguel Angel
MA
García-Pérez
Begoña
B
Pineda
Carlos
C
Hermenegildo
Juan J
JJ
Tarín
Antonio
A
Cano
D019840:2-Propanol; D000469:Alkaline Phosphatase / Q000378:metabolism*; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D001862:Bone Resorption / Q000503:physiopathology; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D002460:Cell Line; D031885:Cimicifuga; D024042:Collagen Type I / Q000652:urine; D050659:Core Binding Factor Alpha 1 Subunit / Q000378:metabolism*; D005260:Female; D006801:Humans; D051379:Mice; D010006:Osteoblasts / Q000187:drug effects / Q000378:metabolism*; D015675:Osteocalcin / Q000378:metabolism*; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology; D010455:Peptides / Q000652:urine; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology* / Q000627:therapeutic use; D017698:Postmenopause / Q000187:drug effects / Q000502:physiology; D011446:Prospective Studies
D015415:Biomarkers; D024042:Collagen Type I; D050659:Core Binding Factor Alpha 1 Subunit; D010455:Peptides; D010936:Plant Extracts; C493709:RUNX2 protein, human; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D000469:Alkaline Phosphatase; D019840:2-Propanol